Organon (OGN) Operating Margin (2020 - 2026)
Organon (OGN) recorded quarterly Operating Margin of 16.1% in Q1 2026, up 15.51% quarter-over-quarter from 13.93% in Q4 2025, and up 30.0% on a YoY basis from 12.38% in Q1 2025.
Organon (OGN) Operating Margin (2020 - 2026) Analysis & Trends
Organon's Operating Margin history runs 7 years deep, the most recent figure standing at 16.1% for Q1 2026.
- In Q1 2026, Operating Margin rose 30.0% year-over-year to 16.1%; the TTM figure through Mar 2026 stood at 18.29% (down 275.0% YoY), while the FY2025 annual figure was 18.19%, up 1556.0% from the prior year.
- Operating Margin was 16.1% for Q1 2026 at Organon, up from 13.93% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 25.98% in Q3 2024 to a low of 36.23% in Q4 2023.
- Historically, Operating Margin has averaged 3.77% across 5 years, with a median of 7.59% in 2022.
- The sharpest annual moves came in 2023 and 2024: Operating Margin tumbled 1752 bps in 2023, then soared 6100 bps in 2024.
- A 5-year view of Operating Margin shows it stood at 32.53% in 2022, then dropped by 11 bps to 36.23% in 2023, then surged by 150 bps to 18.09% in 2024, then declined by 23 bps to 13.93% in 2025, then climbed by 16 bps to 16.1% in 2026.
- The last three Operating Margin figures came in at 16.1% (Q1 2026), 13.93% (Q4 2025), and 22.35% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn | -1.58% |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 16.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.10% |
| Dec 31, 2025 | 13.93% |
| Sep 30, 2025 | 22.35% |
| Jun 30, 2025 | 20.33% |
| Mar 31, 2025 | 15.80% |
| Dec 31, 2024 | 18.09% |
| Sep 30, 2024 | 25.98% |
| Jun 30, 2024 | 24.02% |
| Mar 31, 2024 | -26.45% |
| Dec 31, 2023 | -36.23% |
| Sep 30, 2023 | -35.02% |
| Jun 30, 2023 | -24.00% |
| Mar 31, 2023 | -22.43% |
| Dec 31, 2022 | -32.53% |
| Sep 30, 2022 | -17.50% |
| Jun 30, 2022 | -18.99% |
| Mar 31, 2022 | -7.59% |
| Dec 31, 2021 | -22.65% |
| Sep 30, 2021 | -13.75% |
| Jun 30, 2021 | -9.15% |